Mogamulizumab Shows Sustained Effectiveness in Real-World CTCL Studies
Key Insights
Interim data from three real-world studies reinforce the effectiveness and tolerability of mogamulizumab in treating mycosis fungoides (search) and Sézary syndrome (search).
Patients receiving mogamulizumab experienced improvements in skin symptoms, sleep problems, and body temperature within four weeks, according to the PROSPER study.
The MINT and MIBERIC studies showed that the effectiveness and tolerability of mogamulizumab in real-world clinical practice align with global clinical trial data.
Kyowa Kirin International (KKI) presented interim findings from three real-world studies of mogamulizumab (Poteligeo) in cutaneous T-cell lymphoma (search) (CTCL) at the European Organisation for Research and Treatment of Cancer’s Cutaneous Lymphoma Tumour Group (EORTC-CLTG) annual meeting. The studies, conducted across Europe, the United States, and the United Arab Emirates, aimed to evaluate the effectiveness and tolerability of mogamulizumab in routine clinical practice for patients with mycosis fungoides (search) (MF) and Sézary syndrome (search) (SS). Mogamulizumab is a humanized monoclonal antibody targeting CC-chemokine receptor 4 (CCR4 (search)). It is approved for treating adult patients with MF or SS who have received at least one prior systemic therapy.
MINT and MIBERIC Studies
The MINT study (Germany) and MIBERIC study (Spain and Portugal) assessed the effectiveness and tolerability of mogamulizumab in real-world settings. The interim analyses indicated that the real-world data were broadly consistent with the efficacy and safety data observed in global clinical trials. Notably, no new safety signals were identified in either study, reinforcing the established safety profile of mogamulizumab.
PROSPER Study
The PROSPER study, conducted across the US, UAE, Spain, Italy, Netherlands, and UK, focused on patient-reported outcomes. It investigated the impact of mogamulizumab on symptoms and health-related quality of life in MF and SS patients. Interim results showed that patients experienced improvements in skin symptoms such as pain, itch, flaking, and redness, as well as improvements in sleep problems and body temperature within four weeks of treatment. Furthermore, patients reported improvements in fatigue and health-related quality of life within 24 weeks.
Clinical Implications
Professor Emmanuella Guenova, chief physician of dermatology and venereology at Lausanne University Hospital and chair of the EORTC-CLTG 2024 Annual Meeting, emphasized the importance of real-world evidence in informing clinical decisions. "The real-world evidence being established by Kyowa Kirin is invaluable information for physicians to understand response to treatment in the real world as they determine the best path forwards for their patients," she stated.
Dr. Nicholas Kronfeld, Senior Vice President, Head of Medical Affairs, Kyowa Kirin International, highlighted the company's commitment to providing comprehensive data to the medical community. "Our ongoing research programme in CTCL reinforces mogamulizumab’s clinical utility across a diverse range of patient profiles and healthcare systems," said Dr. Kronfeld.
About Mogamulizumab
Mogamulizumab is a first-in-class humanized monoclonal antibody that targets CCR4 (search), a protein expressed on cancerous cells in MF and SS. By binding to CCR4, mogamulizumab enhances the immune system's ability to destroy these cancerous cells.
About MF and SS
Mycosis fungoides (search) (MF) and Sézary syndrome (search) (SS) are subtypes of cutaneous T-cell lymphoma (search) (CTCL), a rare form of non-Hodgkin’s lymphoma. MF is the most common CTCL subtype, characterized by skin symptoms such as patches, plaques, redness, and tumors. SS is a rarer, more aggressive form with high levels of blood involvement, causing severe itching, erythroderma, and hair loss. CTCL is treatable but generally not curable, highlighting the need for effective treatment options to prolong time to disease progression, reduce disease burden, and improve quality of life.